Clinical trials: DGF
Renal Transplantation
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal…
- Trial name
- NCT00154232
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplant, DGF
Does Early Postoperative Fluid Management Affect Functional Delayed Graft Function After Living Donor Kidney Transplantation?
Fluid management in renal transplantation is of critical importance for optimizing graft function and minimizing complications such as delayed graft function (DGF) and acute kidney injury (AKI).
- Trial name
- NCT07392996
- Where
- Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Ankara University
Delayed Graft Function, Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
The purpose of this study is to evaluate the efficacy of Eculizumab in the prevention of Delayed Graft Function following deceased donor kidney transplantation.
- Conditions
- Delayed Graft Function, Kidney Transplantation, Complement Activity
- Trial name
- NCT01919346
- Testing
- Eculizumab, Normal Saline
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Heeger, Peter, M.D.
DGF, Kidney Transplant; Complications
Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation
Delayed/slow graft function is the most common complication after kidney transplantation with an incidence over 20% and is the result of ischemia-reperfusion injury.
- Trial name
- NCT04414111
- Testing
- Highly suppressive Treg measurement
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- St. Louis University
Kidney Transplantation (Status Post)
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation
This is a phase 2 study to evaluate the efficacy, safety, tolerability and pharmacokinetics of GSK1070806 in subjects undergoing renal transplantation.
- Trial name
- NCT02723786
- Testing
- GSK1070806, 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease, Antibody Mediated Rejection
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a standard of care regimen of…
- Trial name
- BelatPilot (NCT02130817)
- Testing
- Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Delayed Graft Function
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor…
- Trial name
- NCT02474667
- Testing
- ANG-3777
- Where
- 30 sites in United States
- Volunteers
- 253 people
- Sponsor
- Angion Biomedica Corp
Delayed Function of Renal Transplant
Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population
This is an open, randomized, single-center study. The selected patients will be first divided into two major groups according to the type of organ to be transplanted: standard criteria donor (SCD) or extended criteria (ECD)…
- Trial name
- NCT01663805
- Testing
- Everolimus
- Where
- 3 sites in Brazil
- Volunteers
- 80 people
- Sponsor
- MARIO ABBUD FILHO
Delayed Graft Function
Study on Delayed Graft Function Using Paired Kidneys
The study is designed to evaluate the safety and efficacy of an intravenously administered drug in recipients of kidneys from cardiac death donors who are risk for developing delayed graft function.
- Trial name
- NCT01561599
- Testing
- BB3, Normal Saline
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 12 people
- Sponsor
- Angion Biomedica Corp
End Stage Renal Disease, Chronic Kidney Diseases
Berinert (C1INH) vs Placebo for DGF/IRI
This is a Phase I/II double-blind, randomized, placebo-controlled study assessing safety and limited efficacy of intraoperative C1INH (500U/kidney) vs.
- Trial name
- NCT04696146
- Testing
- Berinert
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cedars-Sinai Medical Center
End Stage Renal Disease, Kidney Failure
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high risk for delayed graft function (DGF) may show significant improvement in outcomes post transplant compared with patients that do not…
- Conditions
- End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
- Trial name
- C1INHDGF (NCT02134314)
- Testing
- C1 Esterase Inhibitor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Cedars-Sinai Medical Center
Delayed Graft Function, DGF
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after…
- Conditions
- Delayed Graft Function, DGF, Kidney Transplant
- Trial name
- AWAKE (NCT06830798)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 16 more
- Volunteers
- 450 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Delayed Graft Function
Envarsus in Delayed Graft Function (E-DGF)
Envarsus XR is an extended release tacrolimus designed to deliver tacrolimus more consistently, thus avoiding large fluctuations of tacrolimus trough levels with Envarsus XR compared to immediate release tacrolimus.
- Trial name
- E-DGF (NCT03864926)
- Testing
- Envarsus XR, Tacrolimus
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Wisconsin, Madison
Delayed Graft Function, End Stage Renal Disease
Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
- Conditions
- Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant
- Trial name
- NCT07020832
- Testing
- Pegcetacoplan
- Where
- Brazil
- Sponsor
- Apellis Pharmaceuticals, Inc.
Kidney Transplant; Complications, Liver Transplant; Complications
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after…
- Trial name
- DARE (NCT06130046)
- Testing
- MR-proADM dosage
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Rome Tor Vergata
Kidney Transplantation
ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF
The primary objective of the following randomized open label trial is to demonstrate how low immunological risk patients (no anti HLA immunization and first kidney transplantation) but diagnosed at high-risk of delayed graft…
- Trial name
- PREDICT-DGF (NCT02056938)
- Testing
- Anti-Thymocyte Globulins treatment, Basiliximab treatment
- Where
- 4 sites in France
- Volunteers
- 19 people
- Sponsor
- Nantes University Hospital
Delayed Graft Function
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.
- Trial name
- NCT02145182
- Testing
- Eculizumab
- Where
- 78 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Delayed Graft Function, Kidney Transplantation
The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation
Delayed graft function, defined as the need for dialysis within seven days of kidney transplantation, is a common complication affecting deceased-donor kidney transplant recipients.
- Trial name
- NCT07726134
- Testing
- Furosemide, Mannitol
- Where
- 2 sites in Canada
- Volunteers
- 160 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatocellular Carcinoma (HCC), DGF
A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocellular Carcinoma: a Nomogram and Machine Learning Approaches.
Background: This study aimed to develop a predictive model for delayed graft function (DGF) in liver transplant patients with hepatocellular carcinoma (HCC) based on preoperative biochemical indicators, using both logistic…
- Trial name
- NCT06626724
- Testing
- Liver transplantation
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Jian You
Delayed Graft Function, Kidney Transplantation
The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients
This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant…
- Trial name
- NCT07275632
- Testing
- Vonoprazan fumarate
- Where
- 2 sites in China
- Volunteers
- 47 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University